



Disclosure of Conflict of Interest Form – page 1

Part 1 – completed by Scientific Planning Committee, Speakers, Moderators, Facilitators and Authors.

I **do not** have an affiliation (financial or otherwise) with any for-profit (pharmaceutical, medical device and/or communications firm) and/or not-for-profit organization(s).

I **have/had** an affiliation (financial or otherwise) with a for-profit (pharmaceutical, medical device and/or communications firm) and/or not-for-profit organization(s).

Complete the sections below that apply to you now or during the past two (2) years up to and including the current year. Information includes relationships with for-profit and not-for-profit organizations.

	Planning Committee, Speakers, Moderators, Facilitators, Authors, Other	For-Profit or Not-for-Profit Organization(s)	Description of Relationship
A	Any direct financial relationships including receipt of honoraria, gifts, in-kind compensation, etc.		
B	Membership on advisory boards or speakers' bureaus		
C	Funded grants, research and/or clinical trials		
D	Patents for drug(s) and/or device(s) referred to in the CME/CPD program		
E	Any direct financial relationships that have funded this program		
F	All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity (pharmaceutical, medical device, communications firm)		

Part 2 – completed by Speakers, Moderators, Facilitators and Authors. Check Yes or No.

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e., off-label use of medications).	Yes	No	You must declare all off-label use to the audience during your presentation.
I acknowledge that the National Standard requires that any descriptions of therapeutic options use generic names (or both generic and trade names) and do not reflect exclusivity and branding. If no generic name exists, trade names must be used in a consistent manner.	Yes	No	Failure to do this is a violation of the National Standard and the RCPSC and CFPC requirements.



Disclosure of Conflict of Interest Form – page 2

Part 3 - Identification


Check all that apply:	Scientific Planning Committee	Speaker
	Moderator	Facilitator
	Author	Other:

Event Information

Name of Program/Event	
Date of Program/Event	
Title of Presentation (if applicable)	
Full Name (to appear on schedule)	
Professional Title (to appear on schedule)	

Acknowledgement

I, _____, acknowledge that I have reviewed the declaration form’s guidelines and instructions, and deem all of my information above accurate. I understand that the CME/CPD provider and the Scientific Planning Committee for this program/activity will review all disclosed financial (or otherwise) relationships and determine whether action is required to manage potential, perceived, or real COIs. I also understand that this information will be publicly available.

Signature: _____


Date: _____

Please return signed disclosure form (pages 1 & 2) to: cme.events@usask.ca



Research Funding History (active over the past 2 years)

C. Evans, D. Larocque. Supporting COVID-19 Vaccination Efforts in Saskatchewan Pharmacies. Public Health Agency of Canada (Immunization Partnership Fund). \$359,976, 2021-2023.

H. Tremlett, Y. Zhao, E. Karim, F. Zhu, **C. Evans** (Co-Applicant), R.A. Marrie, J. Fisk, M. Lenzen, K. McKay, J. Hillert, C. Maxwell, K. Harding. Heterogeneity in the MS prodrome and impact on disease progression (PrOMS-HD). National MS Society/MS Society of Canada (jointly funded). \$289,000 USD (\$364,140 CDN), November 2021 – November 2023.

C. Evans, D. Larocque. Harm Reduction and Opioid Agonist Therapy Education for Saskatchewan Healthcare Providers (OAT 3.0). Saskatchewan Ministry of Health. \$250,000, 2021-2024

C. Evans, D. Larocque. Opioid Agonist Therapy (OAT) Training for Saskatchewan Healthcare Students (OAT 2.0). Saskatchewan Ministry of Health. \$100,000, 2021-2022

C. Evans (PI), D. Larocque, C. Bell. Supporting Saskatchewan Healthcare Professionals Navigating Drug Shortages During the COVID-19 Pandemic. Saskatchewan Health Research Foundation Research Connections COVID-19 Rapid Response Program, \$10,000, 2020.

S. Donker, K. Knox. **C. Evans** (Co-Applicant), G. Linassi, M. Levin, I. Poliakov, A. Rajput. Maintaining neuro-connectivity: a virtual approach. Saskatchewan Health Research Foundation Research Connections COVID-19 Rapid Response Program, \$9,400, 2020.

C. Maxwell, S. Bronskill, C. Cotton, **C. Evans**, (Co-Applicant), S. Gill, T. Gomes, A. Gruneir, Q. Guan, T. Hadjistavropoulos, J. Ho, D. Hogan, A. Iaboni, D. Seitz, M. Tadrous, J. Amuah, H. Barry, C. Hughes, K. Lapanie. Understanding and Optimizing Opioid Use in Long Term Care. Canadian Institutes of Health Research (CIHR) Project Grant, \$355,724, 2020-2024

C. Evans. Opioid Agonist Therapy (OAT) Training for Saskatchewan Pharmacy Professionals. Saskatchewan Ministry of Health. \$100,000, 2019-2020

D. Jorgenson, K. Halpape, **C. Evans** (Co-Investigator), E. Landry, K. Alcorn, A. Crawley. An Interdisciplinary Model for Chronic Pain Opioid Management. Health Canada, Substance Use and Addictions Program. \$1,723,853, 2019-2022.

S. Donkers, K. Knox, **C. Evans** (Co-Applicant) C. Kadash, E. Paquin, D. Paquin, E. Kuan, B. Gleim, M. Fieber, H. Lim. Individualized Behaviour Change Strategies for Physical Activity in Multiple Sclerosis. Saskatchewan Health Research Foundation/SCPOR, \$179,972, 2019-2021

H. Tremlett (PI), **C. Evans** (Co-Investigator), RA Marrie, JD Fisk, S. Patten. Disease-modifying Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]. Canadian Institutes of Health Research Foundation Grant, \$1,395,381, 2018 - 2025